MedWorm: Lymphoma

Approved Lymphoma Drug Shows Promise In Early Tests Against Bone Cancer

Cancer / Oncology News From Medical News Today — Fri, 06 Nov 2009 10:00:00 +0100

A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online in the International Journal of Cancer. The study drug, Bortezomib, was found to be effective against bone cancer in human cancer cell studies and in mice. (Source: Cancer / Oncology News From Medical News Today)

MedWorm Sponsor Message: The Lymphoma Research Foundation (LRF) is America's largest lymphoma-focused voluntary health organization devoted exclusively to funding lymphoma research and providing patients and health care professionals with critical information on the disease.

Sunesis' Voreloxin Receives FDA Orphan Drug Designation For Acute Myeloid Leukemia

Health News from Medical News Today — Fri, 06 Nov 2009 10:00:00 +0100

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). (Source: Health News from Medical News Today)

Approved Lymphoma Drug Shows Promise In Early Tests Against Bone Cancer

Health News from Medical News Today — Fri, 06 Nov 2009 10:00:00 +0100

Pivotal Data Published In The Journal Cancer Demonstrate That TREANDA Induced Durable Responses In Relapsed Indolent Non-Hodgkin's Lymphoma

Health News from Medical News Today — Fri, 06 Nov 2009 10:00:00 +0100

Cephalon, Inc. (Nasdaq: CEPH) announced the journal Cancer has published a pivotal study demonstrating that TREANDA® (bendamustine HCl) for Injection induced durable responses in patients with indolent B-cell non-Hodgkin's lymphoma (NHL) whose disease had progressed during or within six months of treatment with rituximab. (Source: Health News from Medical News Today)

Pivotal Data Published In The Journal Cancer Demonstrate That TREANDA Induced Durable Responses In Relapsed Indolent Non-Hodgkin's Lymphoma

Lymphoma / Leukemia News From Medical News Today — Fri, 06 Nov 2009 10:00:00 +0100

Sunesis' Voreloxin Receives FDA Orphan Drug Designation For Acute Myeloid Leukemia

Lymphoma / Leukemia News From Medical News Today — Fri, 06 Nov 2009 10:00:00 +0100

New Data On Bendamustine Offers Hope To Non-Hodgkin's Lymphoma Patients Resistant To Standard Therapy

Health News from Medical News Today — Fri, 06 Nov 2009 09:00:00 +0100

Stem Cell Therapy International, Inc. And Histostem Korea Announce Providing Hematopoietic Stem Cell To Queen Mary Hospital, Hong Kong

Lymphoma / Leukemia News From Medical News Today — Fri, 06 Nov 2009 09:00:00 +0100

Stem Cell Therapy International Inc. (OTCBB: SCII) and its soon to be subsidiary, Histostem Ltd. of South Korea ("Histostem"), announced that they recently supplied hematopoietic stem cells to The Queen Mary Hospital of the University of Hong Kong, China, for treatment of Leukemia patients. (Source: Lymphoma / Leukemia News From Medical News Today)

New Data On Bendamustine Offers Hope To Non-Hodgkin's Lymphoma Patients Resistant To Standard Therapy

Lymphoma / Leukemia News From Medical News Today — Fri, 06 Nov 2009 09:00:00 +0100

New data published today in the journal, Cancer, reveals that three quarters (75%) of patients with indolent B-cell non-Hodgkin's lymphoma (iNHL), responded to treatment with Bendamustine following a single-arm, multicentre study. Significantly, all patients participating in the study had become resistant or were unresponsive to rituximab (the standard treatment for the disease) when used either as a single agent or in combination with other therapies. Professor Brad S. (Source: Lymphoma / Leukemia News From Medical News Today)

An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961

British Journal of Haematology — Fri, 06 Nov 2009 00:00:00 +0100

Burkitt lymphoma (BL), an aggressive B-cell malignancy, is often curable with short intensive treatment regiments. Nearly all BLs contain rearrangements of the MYC/8q24 region; however, recent cytogenetic studies suggest that certain secondary chromosomal aberrations in BL correlate with an adverse prognosis. In this multi-centre study, the frequency and impact on clinical outcome of del(13q) and +7 in addition to MYC rearrangements as detected by fluorescence in situ hybridization (FISH) in children and adolescents with intermediate and high-risk BL registered on Children's Cancer Group study CCG-5961 were investigated. Analysis with 13q14.3 and 13q34 loci specific probes demonstrated deletions of 13q in 38/90 (42%) cases. The loss of either 13q14.3 or 13q34 alone occurred in 14% and 8% r...

Severe paraneoplastic pemphigus in a patient with follicular lymphoma

European Journal of Haematology — Fri, 06 Nov 2009 00:00:00 +0100

(Source: European Journal of Haematology)

Reality of complementary and alternative medicine in lymphoma patients: Hope, hype, or help?

American Journal of Hematology — Fri, 06 Nov 2009 00:00:00 +0100

No abstract. (Source: American Journal of Hematology)

[Comment] Immunosuppression-associated lymphoma in IBD

LANCET — Fri, 06 Nov 2009 00:00:00 +0100

This study is highly relevant: in our experience 30–50% of patients with inflammatory bowel disease are treated with such drugs at some point in the course of their disease The threshold to use thiopurines depends on various factors. The European Crohn's and Colitis Organisation recommends thiopurines for: severe small bowel, ileocaecal, or colonic Crohn's disease if patients have a relapse after or during corticosteroid treatment, in cases of corticosteroid dependency, in the prevention of postoperative recurrence in Crohn's disease, in moderate to severe ulcerative colitis that requires multiple courses of corticosteroids, or in cases of corticodependent or refractory ulcerative colitis. A Cochrane review of the efficacy of thiopurines for inducing remission in active Crohn's disease s...

Dysregulation of the cell survival/anti-apoptotic NF-kappaB pathway by the novel humanized BM-ca anti-CD20 mAb: implication in chemosensitization.

International Journal of Oncology — Thu, 05 Nov 2009 22:17:09 +0100

The objective of this study was to develop novel and fully humanized anti-CD20 monoclonal antibodies with enhanced effector functions and molecular signaling that may potentiate their therapeutic efficacy. Novel humanized anti-CD20 monoclonal antibodies were derived from a chimerized form of murine anti-CD20 1K11791, shown to exert a more potent ADCC, CDC and apoptotic activities compared to rituximab. A representative humanized monoclonal antibody, BM-ca was used to examine its biological effect and molecular signaling using Ramos B-NHL cell line as a model. The studies were also performed in parallel with rituximab treatment for comparison. Ramos cells were treated with various concentrations of BM-ca monoclonal antibody. Inhibition of cell proliferation was observed in a concentration-d...

Spectrum gets CMS nod for radiotherapeutic non-Hodgkin's lymphoma drug

Health Imaging News — Thu, 05 Nov 2009 20:01:48 +0100

The Centers for Medicare & Medicaid Services (CMS) will allow reimbursement for Spectrum Pharmaceuticals radiotherapeutic antibody Zevalin (ibritumomab tiuxetan) for the treatment of patients with previously untreated follicular non-Hodgkin's lymphoma. (Source: Health Imaging News)

Spectrum gets CMS nod for radiotherapeutic non-Hodgkin's lymphoma drug

Health Imaging News — Thu, 05 Nov 2009 20:01:48 +0100

New Data on Bendamustine Offers Hope to Non-Hodgkin's Lymphoma Patients Resistant to Standard Therapy

Drugs.com - Clinical Trials — Thu, 05 Nov 2009 18:55:55 +0100

Cambridge (United Kingdom), 5 November 2009: New data published today in the journal, Cancer, reveals that three quarters (75%) of patients with indolent B-cell non-Hodgkin’s lymphoma (iNHL), responded to treatment with Bendamustine following a... (Source: Drugs.com - Clinical Trials)

Cutaneous tumor lysis syndrome in a patient with HTLV-1 adult T-cell lymphoma/leukemia

Blood — Thu, 05 Nov 2009 17:03:50 +0100

(Source: Blood)

Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity

Blood — Thu, 05 Nov 2009 17:03:49 +0100

Lymphoma idiotype protein vaccines have shown therapeutic potential in previous clinical studies, and results from a completed pivotal, phase 3 controlled trial are promising. However, streamlined production of these patient-specific vaccines is required for eventual clinical application. Here, we show that second-generation, chemokine-fused idiotype DNA vaccines, when combined with myotoxins that induced sterile inflammation with recruitment of antigen-presenting cells at vaccination sites, were exceptional in their ability to provoke memory antitumor immunity in mice, compared with several TLR agonists. The combined vaccination strategy elicited both antigen-specific T-cell responses and humoral immunity. Unexpectedly, vaccine-induced tumor protection was intact in B cell–deficient...

E{micro}-BCL10 mice exhibit constitutive activation of both canonical and noncanonical NF-{kappa}B pathways generating marginal zone (MZ) B-cell expansion as a precursor to splenic MZ lymphoma

Blood — Thu, 05 Nov 2009 17:03:49 +0100

BCL10, required for nuclear factor B (NF-B) activation during antigen-driven lymphocyte responses, is aberrantly expressed in mucosa-associated lymphoid tissue-type marginal zone (MZ) lymphomas because of chromosomal translocations. Eµ-driven human BCL10 transgenic (Tg) mice, which we created and characterize here, had expanded populations of MZ B cells and reduced follicular and B1a cells. Splenic B cells from Tg mice exhibited constitutive activation of both canonical and noncanonical NF-B signaling pathways is associated with increased expression of NF-B target genes. These genes included Tnfsf13b, which encodes the B-cell activating factor (BAFF). In addition, levels of BAFF were significantly increased in sera from Tg mice. MZ B cells of Tg mice exhibited reduced turnover in viv...

A protective role for early oral exposures in the etiology of young adult Hodgkin lymphoma

Blood — Thu, 05 Nov 2009 17:03:48 +0100

The pattern of adolescent/young adult Hodgkin lymphoma (YAHL) suggests causation by a relatively late infection with a common childhood virus, but no causal virus has been found. Susceptibility is heritable and linked to lower interleukin 12 (IL12) levels, which can also result from fewer fecal-oral microbial exposures early in life. We studied twin pairs discordant for YAHL to examine exposures capable of altering the IL12 response and T-helper type 1 (Th1)–Th2 balance. One hundred eighty-eight YAHL-discordant twin pairs from the International Twin Study returned questionnaires (70% response). Exposure history of YAHL case-twins was compared with that of their unaffected control-twins using conditional logistic regression for matched pairs to calculate odds ratios (ORs). Behaviors l...

Pivotal Data Published in the Journal Cancer Demonstrate that TREANDA Induced Durable Responses in Relapsed Indolent Non-Hodgkin's Lymphoma

HSMN NewsFeed — Thu, 05 Nov 2009 16:38:32 +0100

FRAZER, Pa., Nov. 5 (HSMN NewsFeed) -- Cephalon, Inc. (Nasdaq: CEPH ) today announced the journal Cancer has published a pivotal study demonstrating that TREANDA(R) (bendamustine HCl) for Injection induced durable responses in patients with indolent B-ce... Biopharmaceuticals, OncologyCephalon, TREANDA, bendamustine, non-Hodgkin's lymphoma (Source: HSMN NewsFeed)

Approved Lymphoma Drug Shows Promise in Early Tests Against Bone Cancer

Drugs.com - Clinical Trials — Thu, 05 Nov 2009 15:20:09 +0100

ROCHESTER, N.Y., Nov. 5 /PRNewswire-USNewswire/ -- A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in... (Source: Drugs.com - Clinical Trials)

Characterization of Follicular Lymphoma in the Small Intestine Using Double-Balloon Endoscopy

Gastroenterology Research and Practice — Thu, 05 Nov 2009 14:19:33 +0100

We describe endoscopic analysis of 3 cases of follicular lymphoma in the small intestine using double-balloon endoscopy. Double-balloon endoscopy revealed multiple nodular lesions and elevated white patches, multiple polypoid lesions, and scattered white polypoid and nodular lesions in the duodenum and small intestine. Fuji Intelligent Chromo Endoscopy demonstrated small, whitish nodules, and narrow-band imaging showed a coiled, elongated vascular pattern within the elevated lesions. These cases are the first follicular lymphomas in the small intestine evaluated using narrow-band imaging or Fuji Intelligent Chromo Endoscopy to be reported. (Source: Gastroenterology Research and Practice)

Lymphoma Vaccine Trial: One Step Forward in Long Trek

Medscape Today Headlines — Thu, 05 Nov 2009 12:04:34 +0100

This article discusses the results from the trial for BiovaxID, a vaccine for follicular lymphoma, which were presented at this year's ASCO annual meeting. Journal of the National Cancer Institute (Source: Medscape Today Headlines)

Approved lymphoma drug shows promise in early tests against bone cancer

EurekAlert! - Medicine and Health — Thu, 05 Nov 2009 05:00:00 +0100

(University of Rochester Medical Center) A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer. (Source: EurekAlert! - Medicine and Health)

Indolent CD8-positive lymphoid proliferation on the face: part of the spectrum of primary cutaneous small-/medium-sized pleomorphic T-cell lymphoma or a distinct entity?

Journal of Cutaneous Pathology — Thu, 05 Nov 2009 00:00:00 +0100

We report two cases of a CD8-positive lymphoid proliferation presenting as solitary lesions on the ear and nose, respectively. Histopathologically, both cases were characterized by a diffuse non-epidermotropic dermal proliferation of clonal medium-sized CD8-positive T-lymphocytes with a lymphoblast-like appearance, having cells with large folded nuclei, prominent nucleoli and ample amphophilic or pale eosinophilic cytoplasm. Staging procedures excluded systemic involvement, and both lesions were successfully treated with localised radiotherapy without evidence of recurrence after 12 and 24 months' follow up, respectively. Previously reported cases on the ear had similar clinicopathological and immunophenotypical features, and together raise the possibility of a distinct entity, an indolent...

The value of serum free light chains in a case of Waldenstrom's macroglobulinaemia that produces a type I cryoglobulinaemia

Annals of Clinical Biochemistry — Wed, 04 Nov 2009 19:16:54 +0100

We present a case of lymphoplasmacytic lymphoma with type I cryoglobulinaemia that presented with clinical symptoms associated with hyperviscosity syndrome. Quantitation of the paraprotein was not possible using conventional serum protein electrophoresis due to the high serum viscosity, and therefore monitoring was carried out using serial serum free light chain measurements. (Source: Annals of Clinical Biochemistry)

Echocardiographic assessment of a cardiac lymphoma: beyond two-dimensional imaging

European Journal of Echocardiography — Wed, 04 Nov 2009 15:08:55 +0100

We present a case of secondary cardiac lymphoma in an HIV patient presenting with heart failure. Transthoracic echocardiography showed increased left ventricular (LV) wall thickness and an extensive mass in the right cavities with involvement of the tricuspid annulus (Figure 1). Doppler tissue imaging (DTI) showed reduced systolic and diastolic velocities at mitral and tricuspid annulus, compatible with systolic and diastolic myocardial dysfunction, likely owing to infiltration. After 2 weeks of chemotherapy, repeated exam showed significant reduction of the tumour mass and of the LV wall thickness, as well as normalized systolic and diastolic velocities at mitral and tricuspid annulus, as assessed by DTI. Use of transthoracic echocardiography, mostly two-dimensional imaging, has been desc...

In Mycosis Fungoides, Immunophenotypes May Vary Between Skin and Blood

Medscape Internal Medicine Headlines — Wed, 04 Nov 2009 13:35:05 +0100

T-cell immunophenotype of mycosis fungoides involving the skin varies from that involving the blood in more than half the cases of this cutaneous T-cell lymphoma. Medscape Medical News (Source: Medscape Internal Medicine Headlines)

Two Genes Co Operate To Cause Aggressive Leukaemia

Lymphoma / Leukemia News From Medical News Today — Wed, 04 Nov 2009 11:00:00 +0100

Two genes, each one of which is known to cause cancer on its own, together can lead to aggressive leukaemia. This is the conclusion from new research carried out on gene-modified mice at the Sahlgrenska Academy at the University of Gothenburg, Sweden. The discovery has surprised scientists, and may lead to new treatments. The two genes are often present in mutated form in acute leukaemias, but the mutations rarely occur together. (Source: Lymphoma / Leukemia News From Medical News Today)

Clusterin and chemoresistance.

Advances in Cancer Research — Wed, 04 Nov 2009 02:42:03 +0100

Authors: Djeu JY, Wei S Resistance to anticancer agents is one of the primary impediments to effective cancer therapy. Chemoresistance occurs not only to clinically established therapeutic agents but also to novel targeted therapeutics. Both intrinsic and acquired mechanisms have been implicated in drug resistance but it remains controversial which mechanisms are responsible that lead to failure of therapy in cancer patients. Recent focus has turned to clusterin (CLU) as a key contributor to chemoresistance to anticancer agents. Its role has been documented in prostate cancer for paclitaxel/docetaxel resistance as well as in renal, breast, and lung tumor cells. Moreover, it is abnormally upregulated in numerous advanced stage and metastatic cancers spanning prostate, renal, bladder, br...

Multiple myeloma and cutaneous anaplastic large T-cell lymphoma in the same patient: Is there a causal relation?

Journal of Cutaneous Pathology — Wed, 04 Nov 2009 00:00:00 +0100

We report a case of 49-year-old man, with 2-year history of multiple myeloma, presented with a raised, erythematous and ulcerated nodule in the anterior aspect of his right thigh. Histologic examination of biopsy specimen showed a dense dermic infiltrate made of large balastic cells displaying anaplastic morphology with no epidermotropism. Immunohistochemical study showed that tumor cells stained positive with CD30, EMA and CD4, and negative for CD3, CD8, CD5, CD20, CD79a, CD138 and anaplastic lymphoma kinase 1 (ALK or Ki-1). Tangour M, Chelly I, Haouet S, Zitouna M, Kchir N. Multiple myeloma and cutaneous anaplastic large T-cell lymphoma in the same patient: Is there a causal relation? (Source: Journal of Cutaneous Pathology)

Pseudolymphomatous reaction to varicella zoster virus vaccination: role of viral in situ hybridization

Journal of Cutaneous Pathology — Wed, 04 Nov 2009 00:00:00 +0100

We report a 61-year-old female on immunosuppressant medications for rheumatoid arthritis who presented with a subcutaneous nodule at the site of a recent herpes zoster vaccination. Histopathological examination revealed a dense nodular and interstitial mononuclear infiltrate throughout the mid and deep dermis with extension into the superficial subcutaneous fat. Immunohistochemical staining revealed an admixture of T-cells and B-cells, with a predominance of T-cells. These findings are consistent with a pseudolymphoma (PL), a reactive inflammatory disorder that can resemble cutaneous lymphoma and has rarely been described in herpes infections and post-herpetic scars. In situ hybridization studies for VZV were performed and highlighted occasional deep fibroblasts with nuclear positivity for...

High rates of infection associated with the use of maintenance rituximab monotherapy in non-Hodgkin lymphoma

Internal Medicine Journal — Wed, 04 Nov 2009 00:00:00 +0100

(Source: Internal Medicine Journal)

Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma

Cancer — Wed, 04 Nov 2009 00:00:00 +0100

Bendamustine hydrochloride is a novel alkylating agent. In this multicenter study, the authors evaluated the efficacy and toxicity of single-agent bendamustine in patients with rituximab-refractory, indolent B-cell lymphoma.Eligible patients (N = 100, ages 31-84 years) received bendamustine at a dose of 120 mg/m2 by intravenous infusion on Days 1 and 2 every 21 days for 6 to 8 cycles. Histologies included follicular (62%), small lymphocytic (21%), and marginal zone (16%) lymphomas. Patients had received a median of 2 previous regimens (range, 0-6 previous regimens), and 36%were refractory to their most recent chemotherapy regimen. Primary endpoints included overall response rate (ORR) and duration of response (DOR). Secondary endpoints were safety and progression-free survival (PFS).An ORR...

Splenic artery pseudoaneurysm with rupture by transformed splenic marginal zone B cell lymphoma

Annals of Hematology — Tue, 03 Nov 2009 21:11:50 +0100

Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0851-2Authors Yu-Chung Huang, Taipei Veterans General Hospital Division of Hematology & Oncology, Department of Medicine No. 201, Sec. 2, Shipai Rd Taipei 112 TaiwanZhi-Yi Xie, Taipei Veterans General Hospital Division of Hematology & Oncology, Department of Medicine No. 201, Sec. 2, Shipai Rd Taipei 112 TaiwanHsiou-Shan Tseng, Taipei Veterans General Hospital Department of Radiology No. 201, Sec. 2, Shipai Rd Taipei 112 TaiwanChing-Feng Yang, Taipei Veterans General Hospital Department of Pathology No. 201, Sec. 2, Shipai Rd Taipei 112 TaiwanLiang-Tsai Hsiao, Taipei Veterans General Hospital Division of Hematology & Oncology, Department of Medicine No. 201, Sec. 2, Shipai Rd Taipei 112 Taiwan J...

Msh2-dependent DNA repair mitigates a unique susceptibility of B cell progenitors to c-Myc-induced lymphomas [Immunology]

Proceedings of the National Academy of Sciences — Tue, 03 Nov 2009 19:49:57 +0100

C-Myc is one of the most common targets of genetic alterations in human cancers. Although overexpression of c-Myc in the... (Source: Proceedings of the National Academy of Sciences)

ZEVALIN® Receives Positive Reimbursement Ruling Using Average Sales Price (ASP) Methodology

HSMN NewsFeed — Tue, 03 Nov 2009 13:02:46 +0100

ZEVALIN Was Recently Approved by the FDA for the Treatment Of Patients With Previously Untreated Follicular Non-Hodgkins Lymphoma (NHL), Who Achieve A Partial Or Complete Response To First-Line Chemotherapy IRVINE, Calif., Nov 3--(HSMN NewsFeed)--Spect... Biopharmaceuticals, Oncology, ReimbursementSpectrum Pharmaceuticals, ZEVALIN, ibritumomab tiuxetan, non-Hodgkins Lymphoma (Source: HSMN NewsFeed)

ZEVALIN(R) Receives Positive Reimbursement Ruling Using Average Sales Price (ASP) Methodology

HSMN NewsFeed — Tue, 03 Nov 2009 13:02:46 +0100

Immune Therapy Can Protect Against Or Treat Later Lymphoma

Health News from Medical News Today — Tue, 03 Nov 2009 12:00:00 +0100

A role for nuclear translocation of tripeptidyl-peptidase II in reactive oxygen species-dependent DNA damage responses.

Biochemical and Biophysical Research communications — Tue, 03 Nov 2009 11:59:01 +0100

Authors: Preta G, de Klark R, Glas R Responses to DNA damage are influenced by cellular metabolism through the continuous production of reactive oxygen species (ROS), of which most are by-products of mitochondrial respiration. ROS have a strong influence on signaling pathways during responses to DNA damage, by relatively unclear mechanisms. Previous reports have shown conflicting data on a possible role for tripeptidyl-peptidase II (TPPII), a large cytosolic peptidase, within the DNA damage response. Here we show that TPPII translocated into the nucleus in a p160-ROCK-dependent fashion in response to gamma-irradiation, and that nuclear expression of TPPII was present in most gamma-irradiated transformed cell lines. We used a panel of nine cell lines of diverse tissue origin, including ...

FDG PET imaging of childhood sarcomas

Pediatric Blood and Cancer — Tue, 03 Nov 2009 00:00:00 +0100

Positron-emission tomography (PET) imaging using [18F]fluorodeoxyglucose (FDG) is useful for detection, staging, and monitoring a variety of malignancies, including lymphoma, in adults, but its utility in sarcomas, especially soft tissue sarcomas (STS), in children and young adults is not clear.To evaluate the potential utility of FDG PET in the care of STS in children and young adults, we analyzed 46 PET scans in 25 patients acquired over 12 years. Scans were interpreted by two imaging physicians blinded to findings from other imaging studies and clinical information. Results were compared with computed tomography and magnetic resonance imaging, biopsy results, where available, and clinical follow-up of at least 12 months.For a total of 46 scans in 25 patients, there were 25 true-positive...

The diagnostic value of endobronchial ultrasound-guided needle biopsy in lung cancer and mediastinal adenopathy

Diagnostic Cytopathology — Tue, 03 Nov 2009 00:00:00 +0100

Endobronchial ultrasonography (EBUS) has emerged as a new diagnostic tool that allows the bronchoscopist to see beyond the airway, including pulmonary and mediastinal lesion. The real time EBUS-guided transbronchial needle aspiration (TBNA) has advanced the diagnostic yield in primary lung pathology and mediastinal lymph node staging of lung carcinoma. Sixty-four patients (36 males, 28 females, ages ranging from 16 to 86 years) with peribronchial lung lesions and mediastinal and/or hilar lymph node lesions underwent EBUS-TBNA. All patients had intraoperative cytological assessment by smears on aspiration samples or touch preparation on needle core biopsies.The cytological final diagnoses were categorized as negative, suspicious/positive, and non-diagnostic. Forty-nine samples were obtained...

Hepatocellular carcinoma infiltrated with non-Hodgkin’s lymphoma: Report of a case

Surgery Today — Mon, 02 Nov 2009 17:57:20 +0100

Abstract A 70-year-old woman diagnosed to have a hepatitis C virus (HCV) infection was referred to our hospital because of a solitary liver tumor. because of a solitary liver tumor. She underwent a partial hepatectomy, and the tumor was histologically diagnosed as a hepatocellular carcinoma (HCC). diagnosed as a hepatocellular carcinoma (HCC). In addition, a focal follicle consisting of atypical lymphoid cells was seen within the HCC. cells was seen within the HCC. Two months later, she was readmitted because of weakness and rapidly developing abdominal fullness. developing abdominal fullness. An abdominal computed tomography scan showed widespread tumors with ascites. with ascites. A cytological examination of the ascites showed large-sized atypical lymphoid cells. showed...

Immune therapy can protect against or treat later lymphoma

EurekAlert! - Medicine and Health — Mon, 02 Nov 2009 05:00:00 +0100

(Baylor College of Medicine) Specially developed immune system cells that target the common Epstein-Barr virus can protect immune-suppressed bone marrow transplant recipients against lymph system disease and cancers that arise from the viral infection, said a group of researchers led by those from Baylor College of Medicine, the Methodist Hospital and Texas Children's Hospital. (Source: EurekAlert! - Medicine and Health)

Immune therapy can protect against or treat later lymphoma

Baylor College of Medicine News — Mon, 02 Nov 2009 05:00:00 +0100

Specially developed immune system cells that target the common Epstein-Barr virus can protect immune-suppressed bone marrow transplant recipients against lymph system disease and cancers that arise from the viral infection, said a group of researchers led by those from Baylor College of Medicine , The Methodist Hospital and Texas Children's Hospital. "Therapy with EBV-specific CTLs (cytotoxic lymphocytes) was effective for these patients who were severely immune-compromised, as the cells successfully reached the tumor, multiplied and were able to kill tumor cells," said Dr. Helen Heslop, lead author of the study, professor of pediatrics and medicine and a member of the Center for Cell and Gene therapy at BCM, The Methodist Hospital and Texas Children's. The cell remained in the b...

Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.

Ann Oncol — Mon, 02 Nov 2009 00:00:00 +0100

CONCLUSIONS: These results indicate that statins do not influence the clinical prognosis of DLBCL treated with RCHOP. Further studies with larger numbers of patients are warranted to confirm the prognostic significance of statins for patients with DLBCL receiving rituximab-containing chemotherapy. PMID: 19884246 [PubMed - as supplied by publisher] (Source: Ann Oncol)

Improved prognosis for localized malignant lymphomas of the head and neck.

Acta Oto-Laryngologica — Mon, 02 Nov 2009 00:00:00 +0100

Conclusion: In this study we found localized malignant lymphomas of the head and neck to be highly treatable and to have a significantly improved prognosis with recent treatment methods. The head and neck surgeon should keep in mind that the prognosis, especially for diffuse large B-cell lymphoma, has improved if the patient receives the optimal treatment. Objectives: The purpose of this study was to ascertain the current prognosis of localized malignant lymphoma of the head and neck given recent advancements in treatment and diagnostic features, as well as adding histological subtypes to the literature according to the 2001 classification. Methods: We present a retrospective study including a cohort of 100 consecutive patients who had localized malignant lymphoma within the head and neck ...

Recalls and Safety Alerts: TNF Blockers and Cancer in Children

Food and Drug Adminstration (FDA): Patient Safety News — Sun, 01 Nov 2009 03:00:00 +0100

FDA is requiring stronger warnings about an increased risk of lymphoma and other cancers in children and adolescents who are treated with drugs that block tumor necrosis factor. TNF blockers include Remicade (infliximab), Enbrel (etancercept), Humir... (Source: Food and Drug Adminstration (FDA): Patient Safety News)

Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials.

Haematologica — Sun, 01 Nov 2009 00:00:00 +0100

Conclusions The previously reported International Prognostic Index-independent prognostic value of stratification into germinal center/non-germinal center B-cell lymphoma using the expression pattern of CD10, BCL6, and IRF4 was not reproducible in our series. However, other markers and the morphological subtype appear to be of prognostic value. PMID: 19880780 [PubMed - as supplied by publisher] (Source: Haematologica)

Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma.

Haematologica — Sun, 01 Nov 2009 00:00:00 +0100

Conclusions In addition to mantle cell lymphoma, SOX11 is strongly expressed only in lymphoblastic malignancies and Burkitt's lymphomas. Its expression is independent of cyclin D1 (except for weak expression in hairy cell leukemias) and unlikely to be due to translocations in lymphoid neoplasia. PMID: 19880779 [PubMed - in process] (Source: Haematologica)

SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype.

Haematologica — Sun, 01 Nov 2009 00:00:00 +0100

Conclusions SOX11 mRNA and nuclear protein expression is a highly specific marker for both cyclin D1-positive and negative mantle cell lymphoma. PMID: 19880778 [PubMed - in process] (Source: Haematologica)

Mantle cell lymphoma.

Haematologica — Sun, 01 Nov 2009 00:00:00 +0100

Authors: Pileri SA, Falini B PMID: 19880776 [PubMed - in process] (Source: Haematologica)

MR Imaging of Primary Bone Tumors and Tumor-like Conditions in Children

Radiologic Clinics of North America — Sun, 01 Nov 2009 00:00:00 +0100

This article provides a review of the MR imaging features of the major primary malignant and benign bone tumors and tumorlike conditions encountered in the pediatric population. Malignant tumors discussed include osteosarcoma, Ewing sarcoma, chondrosarcoma, lymphoma, and malignant fibrous histiocytoma. Benign lesions discussed include simple bone cysts, aneurysmal bone cysts, giant cell tumor, osteochondroma, enchondroma, chondroblastoma, osteoid osteoma, osteoblastoma, nonossifying fibroma, fibrous dysplasia, osteofibrous dysplasia, hemangioma, and histiocytosis. The use of MR imaging in the diagnosis of these lesions is discussed, and the text is enhanced with imaging examples of the lesions. (Source: Radiologic Clinics of North America)

Metastatic gastric linitis plastica from bladder cancer mimicking a primary gastric carcinoma: a case report.

Korean J Radiol — Sun, 01 Nov 2009 00:00:00 +0100

We present an unusual case, the first to our knowledge, of gastric linitis plastica that resulted from a metastatic urothelial carcinoma of the bladder. PMID: 19885323 [PubMed - in process] (Source: Korean J Radiol)

Primary non-hodgkins lymphoma of the lacrimal sac: mortality-related epiphora.

Orbit — Sat, 31 Oct 2009 22:30:03 +0100

We report a case of primary non-Hodgkins lymphoma of the lacrimal sac in a 60-year-old Asian lady, who presented with persistent epiphora and recurrent medial canthal swelling. Primary lymphoma of the lacrimal sac is rare and it can be easily misdiagnosed. Delayed in diagnosis may be related to mortality. To minimize the risk of overlooking specific pathology it is important to assess the appearance of the lacrimal sac and its surrounding structures intraoperatively. Biopsy of the lacrimal sac is required in cases where specific pathology is suspected. PMID: 19874126 [PubMed - in process] (Source: Orbit)

Rare orbitocranial tumour in an adult.

Orbit — Sat, 31 Oct 2009 22:30:03 +0100

Authors: Mehta A, Chandra M A 35-year-old lady presented with recurrent episodes of painful right upper lid swelling and ptosis of 6 months' duration. The symptoms would subside with oral antibiotics and painkillers. She had also been undergoing treatment for 1 year for multiple painful osteolytic lesions in the long bones and axial skeleton for which no definite diagnosis had been made, despite several radiological and serological investigations having been performed. Computed tomographic scan showed a soft tissue lesion in the superolateral part of the right orbit with erosion of the adjacent bone. Lacrimal gland biopsy showed non-specific inflammatory changes. She was referred for full work-up to exclude lymphoma and metastasis. Magnetic resonance imaging revealed an enhancing soft ...

Guidelines for the use of pralatrexate in non-Hodgkin's lymphoma (NHL) have been updated

PharmacoEconomics and Outcomes News — Sat, 31 Oct 2009 15:27:46 +0100

(Source: PharmacoEconomics and Outcomes News)

Thiopurines may increase risk of lymphoma

Reactions — Sat, 31 Oct 2009 14:02:00 +0100

(Source: Reactions)

The role of cbl family of ubiquitin ligases in gastric cancer exosome-induced apoptosis of Jurkat T cells.

Acta Oncologica — Sat, 31 Oct 2009 11:20:03 +0100

CONCLUSIONS. The Cbl family of ubiquitin ligases might be involved in regulation of exosome-induced apoptosis of Jurkat T cells by increasing PI3K proteasome degradation, inactivation of PI3K/Akt signaling, thus mediating some effects of caspase activation. PMID: 19863226 [PubMed - in process] (Source: Acta Oncologica)

Intussusceptive microvascular growth in human glioma

Clinical and Experimental Medicine — Sat, 31 Oct 2009 10:52:42 +0100

In this study, we have correlated in human glioma the extent of angiogenesis, evaluated as microvascular density, the immunoreactivity of tumor cells to vascular endothelial growth factor (VEGF), vessel diameter and IMG to the tumor stage. Results demonstrate for the first time a relationship in human glioma progression between angiogenesis, VEGF immunoreactivity of tumor cells, vessel diameter and the number of connections of intraluminal tissue folds with the opposite vascular wall, expression of IMG and suggest that IMG could be a mechanism of compensatory vascular growth occurring in human glioma. The advantages are that (1) blood vessels are generated more rapidly; (2) it is energetically and metabolically more economic; (3) the capillaries thereby formed are less leaky. Cont...

Sunesis Completes Enrollment Of Voreloxin REVEAL-1 Trial In Acute Myeloid Leukemia

Health News from Medical News Today — Sat, 31 Oct 2009 08:00:00 +0100

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy. (Source: Health News from Medical News Today)

Immunotherapy Demonstrates Long-Term Success In Treating Lymphoma

Health News from Medical News Today — Sat, 31 Oct 2009 08:00:00 +0100

Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. (Source: Health News from Medical News Today)

Genetic Variations in Xenobiotic Metabolic Pathway Genes, Personal Hair Dye Use, and Risk of Non-Hodgkin Lymphoma

American Journal of Epidemiology — Fri, 30 Oct 2009 22:14:57 +0100

From 1996 to 2000, the authors conducted a population-based case-control study among Connecticut women to test the hypothesis that genetic variation in xenobiotic metabolic pathway genes modifies the relation between hair dye use and risk of non-Hodgkin lymphoma. No effect modifications were found for women who started using hair dyes in 1980 or afterward. For women who started using hair dye before 1980 as compared with never users, a statistically significantly increased risk of non-Hodgkin lymphoma was found for carriers of CYP2C9 Ex3-52C>T TT/CT genotypes (odds ratio (OR) = 2.9, 95% confidence interval (CI): 1.4, 6.1), CYP2E1 -332T>A AT/AA genotypes (OR = 2.0, 95% CI: 1.2, 3.4), a homozygous or heterozygous 3-base-pair deletion in intron 6 of GSTM3 (OR = 2.3, 95% CI: 1.3, 4.1), G...

Body Size, Recreational Physical Activity, and B-Cell Non-Hodgkin Lymphoma Risk Among Women in the California Teachers Study

American Journal of Epidemiology — Fri, 30 Oct 2009 22:14:57 +0100

Nutritional status and physical activity are known to alter immune function, which may be relevant to lymphomagenesis. The authors examined body size measurements and recreational physical activity in relation to risk of B-cell non-Hodgkin lymphoma (NHL) in the prospective California Teachers Study. Between 1995 and 2007, 574 women were diagnosed with incident B-cell NHL among 121,216 eligible women aged 22–84 years at cohort entry. Multivariable-adjusted relative risks and 95% confidence intervals were estimated by fitting Cox proportional hazards models for all B-cell NHL combined and for the 3 most common subtypes: diffuse large B-cell lymphoma, follicular lymphoma, and B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. Height was positively associated with risk of al...

Paracoccidioidomycosis

Paediatric Respiratory Reviews — Fri, 30 Oct 2009 15:16:00 +0100

Summary: Paracoccidioidomycosis is a systemic fungal infection caused by Paracoccidoides brasiliensis. The infection is endemic in subtropical areas of Latin America and has a high prevalence in Brazil. The disease is acquired by airborne inhalation of conidia and is frequently observed in adult male rural workers. The juvenile type of this mycosis is less prevalent (5-10% of clinical cases) and attacks both sexes. This clinical form occurs in children and adolescents and has a subacute course with fever, toxemia, loss of weight, adenopathy, hepatoesplenomegaly, anaemia and eosinophilia. Radiologic abnormalities in the lung fields may be seen. Mucous membrane lesions occasionally occur. The clinical presentation resembles severe tuberculosis, leukaemia or lymphoma. The diagnosis is confirm...

Treatment of cutaneous tumors with topical 5% imiquimod cream

Clinics — Fri, 30 Oct 2009 14:28:46 +0100

CONCLUSIONS: Our experience confirms imiquimod as an effective treatment option for several types of cutaneous tumors, especially in patients without the cutaneous comorbidities cited above and with low-risk tumors. Imiquimod has a relatively low cost compared to other therapeutic options and can be delivered via ambulatory care to patients with surgery contraindications, and its side effects are tolerable. (Source: Clinics)

Lymphoma Research Foundation Announces Recipients Of CLL/SLL Research Initiative Grants

Health News from Medical News Today — Fri, 30 Oct 2009 07:00:00 +0100

The Lymphoma Research Foundation (LRF) is pleased to announce that David Frank, MD, PhD of the Dana-Farber Cancer Institute and Thomas Kipps, MD, PhD, Moores Cancer Center, University of California, San Diego are the recipients of the second round of funding under the Foundation's Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Research Initiative. (Source: Health News from Medical News Today)

Exercise helps lymphoma patients

Health News - UPI.com — Fri, 30 Oct 2009 05:30:43 +0100

EDMONTON, Alberta, Oct. 30 (UPI) -- Canadian researchers say aerobic exercise benefits lymphoma patients -- even those on chemotherapy. (Source: Health News - UPI.com)

Immunotherapy demonstrates long-term success in treating lymphoma

EurekAlert! - Medicine and Health — Fri, 30 Oct 2009 04:00:00 +0100

This study was published online today in Blood, the official journal of the American Society of Hematology. (Source: EurekAlert! - Medicine and Health)

[Comment] Progress in primary CNS lymphoma

LANCET — Fri, 30 Oct 2009 00:00:00 +0100

Primary CNS lymphoma is an enigmatic and challenging disease—its uncertainties begin with aetiology and extend to the potential for treatment-related toxicity years later. The malignant lymphocytes' tropism for the CNS remains unexplained, both in terms of disease origin and the low incidence of systemic relapse. Presentation ranges from many months of intermittent vague neurological symptoms to rapidly progressive severe sensorimotor and cognitive impairment. Pathological diagnosis can be a problem and hampered by the empirical use of corticosteroids. (Source: LANCET)

[Articles] High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial

LANCET — Fri, 30 Oct 2009 00:00:00 +0100

Chemotherapy with high-dose methotrexate is the conventional approach to treat primary CNS lymphomas, but superiority of polychemotherapy compared with high-dose methotrexate alone is unproven. We assessed the effect of adding high-dose cytarabine to methotrexate in patients with newly diagnosed primary CNS lymphoma. (Source: LANCET)

Age-related EBV-associated B-cell lymphoproliferative disorders: Diagnostic approach to a newly recognized clinicopathological entity

Pathology International — Fri, 30 Oct 2009 00:00:00 +0100

EBV is prevalent among healthy individuals, and is implicated in numerous reactive and neoplastic processes in the immune system. The authors originally identified a series of senile or age-related EBV-associated B-cell lymphoproliferative disorders (LPD) bearing a resemblance to immunodeficiency-associated ones, which may be associated with immune senescence in the elderly and which are now incorporated into the 2008 World Health Organization lymphoma classification as EBV-positive diffuse large B-cell lymphoma (DLBCL) of the elderly. This newly described disease is pathologically characterized by a proliferation of atypical large B cells including Reed[ndash]Sternberg-like cells with reactive components, which pose a diagnostic problem for pathologists. Clinically, this disease may prese...

Clinicopathological features of syphilitic gastritis in Korean patients

Pathology International — Fri, 30 Oct 2009 00:00:00 +0100

Syphilitic gastritis is difficult to diagnose without a history of syphilis, because endoscopic and microscopic findings can simulate gastric cancer or lymphoma. Herein are reported two cases of syphilitic gastritis and analysis of the clinicopathological characteristics of 11 cases in Korean subjects, including nine previously reported ones. The two present patients were 25- and 32-year-old men with epigastric pain. The gastroduodenoscopy features were similar: multiple erosive or ulcerative lesions in whole gastric mucosa. Microscopically, gastric mucosa contained severe chronic active gastritis involving submucosa with crypt abscesses, venulitis and granulomas, suggesting unusual infectious gastritis. Numerous spirochetes were identified on silver staining, and serological tests for syp...

HIV lumbosacral radiculoplexus neuropathy mimicking lymphoma: Diffuse infiltrative lymphocytosis syndrome (DILS) restricted to nerve?

Muscle and Nerve — Fri, 30 Oct 2009 00:00:00 +0100

Diffuse infiltrative lymphocytosis syndrome (DILS) is a hyperimmune reaction against HIV. It leads to MHC-restricted clonal expansion of CD8 T cells characterized by circulating CD8 hyperlymphocytosis and CD8 T-cell infiltration in organs. Our patient presented with painful lumbosacral radiculoplexus neuropathy and tested positive for HIV. Nerve biopsy showed large collections of CD8 lymphocytes suspicious for lymphoma. Symptoms, signs, and repeat biopsy improved with antiretroviral treatment. The presentation and treatment response suggest that this case is localized DILS. Muscle Nerve, 2009 (Source: Muscle and Nerve)

Granuloma Annulare Heralding Angioimmunoblastic T-Cell Lymphoma in a Patient With a History of Epstein-Barr Virus-Associated B-Cell Lymphoma [DIAGNOSIS IN ONCOLOGY]

Journal of Clinical Oncology — Thu, 29 Oct 2009 22:02:56 +0100

(Source: Journal of Clinical Oncology)

Primary Testicular Diffuse Large B-Cell Lymphoma: A Population-Based Study on the Incidence, Natural History, and Survival Comparison With Primary Nodal Counterpart Before and After the Introduction of Rituximab [Hematologic Malignancies]

Journal of Clinical Oncology — Thu, 29 Oct 2009 22:02:56 +0100

Conclusion The incidence of testicular DLBCL is increasing. Compared with nodal DLBCL, testicular DLBCL patients have a better overall prognosis but are at higher risk of late disease-related deaths. The introduction of rituximab in clinical practice does not seem to improve their early outcome. (Source: Journal of Clinical Oncology)

Young Adults With Acute Lymphoblastic Leukemia Have an Excellent Outcome With Chemotherapy Alone and Benefit From Intensive Postinduction Treatment: A Report From the Children's Oncology Group [Hematologic Malignancies]

Journal of Clinical Oncology — Thu, 29 Oct 2009 22:02:55 +0100

Conclusion Young adult patients with ALL showing a rapid response to induction chemotherapy benefit from early intensive postinduction therapy but do not benefit from a second interim maintenance and delayed intensification phase. Given the excellent outcome with this chemotherapy, there seems to be no role for the routine use of allogeneic stem-cell transplantation in first remission for young adults with ALL. (Source: Journal of Clinical Oncology)

Phase II Study of Yttrium-90-Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma [Hematologic Malignancies]

Journal of Clinical Oncology — Thu, 29 Oct 2009 22:02:55 +0100

Conclusion The single-agent activity of 90Y–ibritumomab tiuxetan and its favorable safety profile warrant its further development for the treatment of MCL. (Source: Journal of Clinical Oncology)

CD20-targeted tetrameric interferon-{alpha}, a novel and potent immunocytokine for the therapy of B-cell lymphomas

Blood — Thu, 29 Oct 2009 16:03:30 +0100

Interferon- (IFN-) has direct inhibitory effects on some tumors and is a potent stimulator of both the innate and adaptive immune systems. A tumor-targeting antibody-IFN- conjugate (mAb-IFN-) could kill by direct actions of the monoclonal antibody (mAb) and IFN- on tumor cells and also potentiate a tumor-directed immune response. The modular Dock-and-Lock method (DNL) was used to generate 20-2b, the first immunocytokine having 4 cytokine (IFN-2b) groups that are fused to the humanized anti-CD20 mAb, veltuzumab. Additional mAb-IFN- constructs, each retaining potent IFN-2b biologic activity, also were produced by DNL. The 20-2b shows enhanced antibody-dependent cellular cytotoxicity compared with veltuzumab but lacks complement-dependent cytotoxicity. The 20-2b inhibits in vitro proliferatio...

C/EBP{beta} regulates transcription factors critical for proliferation and survival of multiple myeloma cells

Blood — Thu, 29 Oct 2009 16:03:30 +0100

CCAAT/enhancer-binding protein β (C/EBPβ), also known as nuclear factor–interleukin-6 (NF-IL6), is a transcription factor that plays an important role in the regulation of growth and differentiation of myeloid and lymphoid cells. Mice deficient in C/EBPβ show impaired generation of B lymphocytes. We show that C/EBPβ regulates transcription factors critical for proliferation and survival in multiple myeloma. Multiple myeloma cell lines and primary multiple myeloma cells strongly expressed C/EBPβ, whereas normal B cells and plasma cells had little or no detectable levels of C/EBPβ. Silencing of C/EBPβ led to down-regulation of transcription factors such as IRF4, XBP1, and BLIMP1 accompanied by a strong inhibition of proliferation. Further, silencing o...

Clonotypic B cells in classic Hodgkin lymphoma

Blood — Thu, 29 Oct 2009 16:03:30 +0100

(Source: Blood)

Response: Hodgkin lymphoma stem cells

Blood — Thu, 29 Oct 2009 16:03:30 +0100

(Source: Blood)

Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors

Blood — Thu, 29 Oct 2009 16:03:29 +0100

In conclusion, 7.5 µg/kg per day lenograstim proved to be safe and effective for mobilizing hematopoietic stem cells for allogeneic transplantation. Long-term monitoring of healthy PBSC donors remains important to guarantee the safety standards of PBSC mobilization and collection. (Source: Blood)

Plasmacytoid Dendritic Cells: Physiologic Roles and Pathologic States

Advances in Anatomic Pathology — Thu, 29 Oct 2009 14:57:11 +0100

Plasmacytoid dendritic cells (PDCs) have perplexed pathologists for decades, undergoing multiple adjustments in nomenclature as their lineage and functions have been characterized. Although PDCs account for less than 0.1% of peripheral blood mononuclear cells, they serve as a principal source of interferon-[alpha] and are also known as interferon-I producing cells (IPCs). Upon activation in vitro, they can differentiate into dendritic cells, and recent studies have substantiated a potential role in antigen presentation. Thus, PDCs may act as a link between innate and adaptive immunity. Normally found in small quantities in primary and secondary lymphoid organs, PDCs accumulate in a variety of inflammatory conditions, including Kikuchi-Fujimoto lymphadenopathy, hyaline-vascular Castleman di...

Innovative National Clinical Trial Network Launched By Rare Cancer Charity

Health News from Medical News Today — Thu, 29 Oct 2009 12:00:00 +0100

Myeloma UK has launched an innovative Clinical Trial Network designed to transform the way drugs for the bone marrow cancer myeloma are tested and accessed in the UK. (Source: Health News from Medical News Today)

Angiotropic T cell lymphoma associated with dermatotnyositis

Irish Journal of Medical Science — Thu, 29 Oct 2009 06:51:24 +0100

Content Type Journal ArticleDOI 10.1007/BF03169782 Journal Irish Journal of Medical ScienceOnline ISSN 1863-4362Print ISSN 0021-1265 Journal Volume Volume 170 Journal Issue Volume 170, Supplement 2 / January, 2001 (Source: Irish Journal of Medical Science)

Whole-Body Sleeping Beauty Mutagenesis Can Cause Penetrant Leukemia/Lymphoma and Rare High-Grade Glioma without Associated Embryonic Lethality

Cancer Research — Thu, 29 Oct 2009 04:08:15 +0100

The Sleeping Beauty (SB) transposon system has been used as a somatic mutagen to identify candidate cancer genes. In previous studies, efficient leukemia/lymphoma formation on an otherwise wild-type genetic background occurred in mice undergoing whole-body mobilization of transposons, but was accompanied by high levels of embryonic lethality. To explore the utility of SB for large-scale cancer gene discovery projects, we have generated mice that carry combinations of different transposon and transposase transgenes. We have identified a transposon/transposase combination that promotes highly penetrant leukemia/lymphoma formation on an otherwise wild-type genetic background, yet does not cause embryonic lethality. Infiltrating gliomas also occurred at lower penetrance in these mice. SB-induc...

Identification of Key Regions and Genes Important in the Pathogenesis of Sezary Syndrome by Combining Genomic and Expression Microarrays

Cancer Research — Thu, 29 Oct 2009 04:08:15 +0100

In this study, we used single nucleotide polymorphism and comparative genomic hybridization array to study DNA copy number changes and loss of heterozygosity for 28 patients affected by Sézary syndrome (SS), a rare form of cutaneous T-cell lymphoma (CTCL). Our data identified, further confirming previous studies, recurrent losses of 17p13.2-p11.2 and 10p12.1-q26.3 occurring in 71% and 68% of cases, respectively; common gains were detected for 17p11.2-q25.3 (64%) and chromosome 8/8q (50%). Moreover, we identified novel genomic lesions recurring in >30% of tumors: loss of 9q13-q21.33 and gain of 10p15.3-10p12.2. Individual chromosomal aberrations did not show a significant correlation with prognosis; however, when more than three recurrent chromosomal alterations (gain or loss) wer...

Epigenetic Inactivation of the Circadian Clock Gene BMAL1 in Hematologic Malignancies

Cancer Research — Thu, 29 Oct 2009 04:08:15 +0100

Disruption of circadian rhythms, daily oscillations in biological processes that are regulated by an endogenous clock, has been linked to tumorigenesis. Normal and malignant tissues often show asynchronies in cell proliferation and metabolic rhythms. Cancer chronotherapy takes biological time into account to improve the therapy. However, alterations of the circadian clock machinery genes have rarely been reported in human cancer. Herein, we show that the BMAL1 gene, a core component of the circadian clock, is transcriptionally silenced by promoter CpG island hypermethylation in hematologic malignancies, such as diffuse large B-cell lymphoma and acute lymphocytic and myeloid leukemias. We also describe how BMAL1 reintroduction in hypermethylated leukemia/lymphoma cells causes growth inhibit...

[Review] Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009

The Lancet Oncology — Thu, 29 Oct 2009 00:00:00 +0100

T-cell and natural-killer (NK)-cell lymphomas are neoplasms with geographical variations in frequencies. T-cell lymphomas are more prevalent in Asia than in Europe and North America, and NK-cell lymphomas occur almost exclusively in Asia and South America. These low frequencies mean that the diagnosis and optimum treatment of patients with T-cell and NK-cell lymphomas have not been studied prospectively in randomised controlled trials. Because T-cell and NK-cell lymphomas are more prevalent in Asia, the establishment of management recommendations by Asian oncologists in collaboration with international experts is pertinent. This review outlines guidelines commensurate with different levels of health-care resources and expertise. Consensus statements were formulated for diagnosis, staging, ...

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma

British Journal of Haematology — Thu, 29 Oct 2009 00:00:00 +0100

Romidepsin has shown promise in the treatment of T-cell lymphomas, and so we evaluated molecular endpoints gathered from 61 patients enrolled on a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma at the National Institutes of Health. The endpoints included histone H3 acetylation and ABCB1 gene expression in peripheral blood mononuclear cells (PBMCs); ABCB1 gene expression in tumour biopsy samples; and blood fetal haemoglobin levels (HbF), all of which were increased following romidepsin treatment. The fold increase in histone acetylation in PBMCs at 24 h was weakly to moderately well correlated with the pharmacokinetic parameters Cmax and area under the curve (AUC)last ([rho] = 0·37, P = 0·03 and [rho] = 0·36, P = 0·03 respectively) and inversely associated with...

[Results of immuno-chemotherapeutic treatment of patients with diffuse large B-cell lymphoma.]

Orvosi Hetilap — Thu, 29 Oct 2009 00:00:00 +0100

In this study, efficacy of R-CHOP and R-CHOP-like treatments was analysed. Results were compared to the data of historical patients only receiving CHOP treatment or CHOP-like treatment. Between September 2002 and April 2005, 140 newly diagnosed, untreated DLBCL patients started to receive R-CHOP treatment in a single centre. The eligibility criteria included advanced stage (clinical stages III-IV), or large tumour size (>7 cm) and/or symptom B or extranodal manifestation in the case of clinical stages I-II. The results were compared to the data of 130 patients only receiving CHOP treatment in the past. In the patients receiving R-CHOP, the therapeutic outcomes were superior for all parameters. During an average follow-up period of 44 or 52 months, the overall remission rate was 73.6% in...

A co-dependent requirement of xBcl9 and Pygopus for embryonic body axis development in Xenopus

Developmental Dynamics — Thu, 29 Oct 2009 00:00:00 +0100

The Wnt/[beta]-catenin transcriptional activation complex requires the adapter protein Pygopus (Pygo), which links the basal transcription machinery to [beta]-catenin, by its association with legless (Lgs)/ B-cell lymphoma-9 (Bcl9). Pygo was shown to be required for development in vertebrates, but the role of Lgs/Bcl9 is unknown. We identified an amphibian orthologue of Lgs/Bcl9, XBcl9, which interacted biochemically with X[beta]-catenin and XPygo2. The body axis promoting ability of X[beta]-catenin was diminished when residues required for its interaction with XBcl9 were mutated. In blastula embryos, XBcl9 was transiently preferentially expressed in nuclei of dorsoanterior cells and ectopically expressed XBcl9 required XPygo2 to localize to nuclei. Furthermore, while neither XBcl9 nor XPy...

Treatment-Related Burkitt's Lymphoma: Literature Review and Case Report of Successful Treatment with Rituximab Monotherapy

Karger Publishers — Wed, 28 Oct 2009 23:00:00 +0100

Acta Haematol 2009;122:211-215 (DOI:10.1159/000253028) (Source: Karger Publishers)

Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in Assessing Prognosis and Predicting First-Line Treatment Efficacy in Follicular Lymphoma Patients

Karger Publishers — Wed, 28 Oct 2009 23:00:00 +0100

Acta Haematol 2009;122:193-199 (DOI:10.1159/000253026) (Source: Karger Publishers)

Exercise Good for Lymphoma Patients

Disabled World — Wed, 28 Oct 2009 15:57:32 +0100

Lymphoma patients who received the exercise intervention reported significantly improved physical functioning, overall quality of life, less fatigue, increased happiness, less depression and an improvement in lean body mass. (Source: Disabled World)

Hematology: Hodgkin lymphoma survivors: high risk of stroke and TIA

Nature Clinical Practice Oncology — Wed, 28 Oct 2009 13:43:56 +0100

Nature Reviews Clinical Oncology 6, 617 (2009). doi:10.1038/nrclinonc.2009.152 Author: Lisa Hutchinson (Source: Nature Clinical Practice Oncology)

Hematology: The case against rituximab maintenance

Nature Clinical Practice Oncology — Wed, 28 Oct 2009 13:43:56 +0100

This article discusses the results of randomized trials that suggest patients with follicular lymphoma should not receive rituximab maintenance therapy. (Source: Nature Clinical Practice Oncology)

Hematology: Follicular lymphoma: maintenance therapy is (often) indicated

Nature Clinical Practice Oncology — Wed, 28 Oct 2009 13:43:56 +0100

This article discusses the results of randomized trials that suggest that specific subgroups of patients with follicular lymphoma should receive maintenance therapy with rituximab. (Source: Nature Clinical Practice Oncology)

Exercise for lymphoma patients

Medicineworld.org: New Article Alert — Wed, 28 Oct 2009 12:04:38 +0100

A healthy dose of exercise is good medicine, even for lymphoma patients receiving chemotherapy, University of Alberta scientists have found. The Healthy Exercise for Lymphoma Patients (HELP) trial, a three-year study led by Kerry Courneya, Canada Research Chair in physical activity and cancer in the Faculty of Physical Education and Recreation, observed that a regimen of aerobic exercise training produced significant improvements in physical functioning and overall quality of life benefits in patients with lymphoma........ (Source: Medicineworld.org: New Article Alert)

High-dose temsirolimus improved PFS, response rates in mantle cell lymphoma

HemOncToday.com — Wed, 28 Oct 2009 11:46:00 +0100

(Source: HemOncToday.com)

Lymphoma Patients Benefit From Exercise

Health News from Medical News Today — Wed, 28 Oct 2009 11:00:00 +0100

A healthy dose of exercise is good medicine, even for lymphoma patients receiving chemotherapy, University of Alberta researchers have found. (Source: Health News from Medical News Today)

Vitamin D: How to Determine Your Optimal Dose

NaturalNews.com — Wed, 28 Oct 2009 07:00:00 +0100

(NaturalNews) In the wide world of supplements, vitamin D is the superstar. For the last few years, this humble nutrient has been featured prominently in allopathic and alternative circles alike. It has basked in the rays of media publicity, and has survived an onslaught of scientific scrutiny. And while such widespread publicity is often good cause for skepticism in the realm of health and medicine, vitamin D appears to be the real deal. Whether we`re talking about heart disease, cancer, diabetes, multiple sclerosis, or Alzheimer`s disease, the "sunshine vitamin" delivers benefits unseen before our time (1).Given the remarkably powerful benefits of vitamin D, many find themselves wondering how to actually go about obtaining it. We know that vitamin D is good for us, but how much do we nee...

Lymphoma Research Foundation announces recipients of CLL/SLL Research Initiative grants

EurekAlert! - Medicine and Health — Wed, 28 Oct 2009 04:00:00 +0100

(Lymphoma Research Foundation) The Lymphoma Research Foundation is pleased to announce that David Frank, M.D., Ph.D., of the Dana-Farber Cancer Institute and Thomas Kipps, M.D., Ph.D., Moores Cancer Center, University of California, San Diego, are the recipients of the second round of funding under the Foundation's Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Research Initiative. (Source: EurekAlert! - Medicine and Health)

Outcomes for lymphoid malignancies in the Nurses' Health Study (NHS) as compared to the Surveillance, Epidemiology and End Results (SEER) Program

Hematological Oncology — Wed, 28 Oct 2009 00:00:00 +0100

Vital statistics for the lymphoid malignancies obtained from the Surveillance, Epidemiology and End Results (SEER) Program have seldom been directly compared to data from alternative national databases. While SEER is recognized as the standard, some lymphoid malignancies - especially the chronic ones - may be underreported. We compared the incidence, all-cause and cause-specific mortality for Hodgkin's lymphoma (HL), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL) in SEER to that in the Nurses' Health Study (NHS), a national cohort study of 121 700 female registered nurses, matching for age and race. In over 2.5 million person-years, the incidence of HL was the same as in SEER (SIR = 1.01 [0.75, 1.26]), while the incidence of NHL, CLL and MM were...

Human Follicular Lymphoma CD39+-Infiltrating T Cells Contribute to Adenosine-Mediated T Cell Hyporesponsiveness.

Journal of Immunology — Wed, 28 Oct 2009 00:00:00 +0100

In this study, we identify pericellular adenosine, interacting with T cell-associated G protein-coupled A(2A/B) adenosine receptors (AR), as contributing to FL T cell hyporesponsiveness. In a subset of FL patient samples, treatment of lymph node mononuclear cells (LNMC) with specific A(2A/B) AR antagonists results in an increase in IFN-gamma or IL-2 secretion upon anti-CD3/CD28 Ab stimulation, as compared with that seen without inhibitors. In contrast, treatment with an A(1) AR antagonist had no effect on cytokine secretion. As the rate limiting step for adenosine generation from pericellular ATP is the ecto-ATPase CD39, we next show that inhibition of CD39 activity using the inhibitor ARL 67156 partially overcomes T cell hyporesponsiveness in a subset of patient samples. Phenotypic charac...

Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy

Annals of Oncology — Tue, 27 Oct 2009 20:01:11 +0100

Conclusion: Sixty-nine per cent of patients with residual FDG avidity after ABVD were free of disease after consolidative RT, indicating a majority of patients with persistent lymphoma can be cured by sterilizing this PET-positive disease. (Source: Annals of Oncology)

Early FDG-PET response–adapted risk stratification and further therapeutic decision-making in lymphoma: will this replace the established prognostic indices and be the standard-of-care in clinical management?

European Journal of Nuclear Medicine and Molecular Imaging — Tue, 27 Oct 2009 17:57:01 +0100

Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00259-009-1296-5Authors Sandip Basu, Tata Memorial Hospital Annexe Radiation Medicine Centre (BARC) Parel Bombay 400012 India Journal European Journal of Nuclear Medicine and Molecular ImagingOnline ISSN 1619-7089Print ISSN 1619-7070 (Source: European Journal of Nuclear Medicine and Molecular Imaging)

The cytological diagnosis of paediatric renal tumours

Journal of Clinical Pathology — Tue, 27 Oct 2009 17:01:57 +0100

Fine needle aspiration cytology (FNAC) is used for preoperative diagnosis of paediatric renal tumours, especially in centres where preoperative chemotherapy is advocated in Wilms’ tumour. This review focuses on salient cytological features in specific paediatric renal tumours, the approach to resolving a differential diagnosis and the role of ancillary methods in diagnosis of paediatric renal tumours. Crucial differential diagnoses include distinguishing: Wilms’ tumour from benign tumours in the kidney like multicystic nephroma or congenital mesoblastic nephroma; aggressive non-Wilms’ tumours of kidney like rhabdoid tumour of kidney; and Wilms’ tumour from other paediatric round cell sarcomas like neuroblastoma, non-Hodgkin lymphoma etc. An approach based on classif...

New time-dependent approach to analyse the prognostic significance of immunohistochemical biomarkers in colon cancer and diffuse large B-cell lymphoma

Journal of Clinical Pathology — Tue, 27 Oct 2009 17:01:57 +0100

Conclusions: Time-dependent ROC curve analysis is a novel tool for identifying potential immunohistochemical prognostic markers across varying follow-up times. Use of this tool could facilitate the identification of high-risk patients not only with colon cancer and DLBCL but with a range of other tumour types. (Source: Journal of Clinical Pathology)

FDA Approves New Treatment For Chronic Lymphocytic Leukemia

Health News from Medical News Today — Tue, 27 Oct 2009 11:00:00 +0100

The U.S. Food and Drug Administration approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow. Arzerra is approved for patients with CLL whose cancer is no longer being controlled by other forms of chemotherapy. (Source: Health News from Medical News Today)

Primary small cell carcinoma of the pleura: a case report with immunohistochemical and molecular genetic analyses of KIT and PDGFRA genes

Medical Oncology — Tue, 27 Oct 2009 09:05:58 +0100

Abstract An extremely rare case of primary small cell carcinoma of the pleura with an emphasis on KIT and platelet-derived growth factor receptor-α (PDGFRA) genes is reported here. A 67-year-old man underwent left testicular orchiectomy because of a testicular tumor. The tumor was immunohistochemically shown to be diffuse large B-cell lymphoma. The patient was treated with chemotherapy and radiation and followed up in our hospital. Eight years after the orchiectomy, the patient (75 years old) developed left pleural tumor and pleural effusion, and a biopsy was performed. The biopsy revealed a medullary malignant tumor consisting of small round and spindle cells. The following three possibilities were considered: recurrent lymphoma, mesothelioma, and small cell carcinoma...

Exercise is good medicine for lymphoma patients

EurekAlert! - Medicine and Health — Tue, 27 Oct 2009 04:00:00 +0100

(University of Alberta) A healthy dose of exercise is good medicine, even for lymphoma patients receiving chemotherapy, University of Alberta researchers have found. (Source: EurekAlert! - Medicine and Health)

Comprehensive analyses and characterization of haemophagocytic lymphohistiocytosis in Vietnamese children

British Journal of Haematology — Tue, 27 Oct 2009 00:00:00 +0100

In conclusion, the majority of HLH cases are associated with virus infections in Vietnamese children. Familial HLH is rare. The frequent reactivation and high mortality demands a more appropriate therapeutic regimen in tropical areas like Vietnam. (Source: British Journal of Haematology)

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy

Journal of Hematology and Oncology — Tue, 27 Oct 2009 00:00:00 +0100

The mammalian target of rapamycin (mTOR) is an intracellular serine/threonine protein kinase positioned at a central point in a variety of cellular signaling cascades. The established involvement of mTOR activity in the cellular processes that contribute to the development and progression of cancer has identified mTOR as a major link in tumorigenesis. Consequently, inhibitors of mTOR, including temsirolimus, everolimus, and ridaforolimus (formerly deforolimus) have been developed and assessed for their safety and efficacy in patients with cancer. Temsirolimus is an intravenously administered agent approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for the treatment of advanced renal cell carcinoma (RCC). Everolimus is an oral agent that has recen...

Clinical Cancer Research — Tue, 27 Oct 2009 00:00:00 +0100

Conclusions derived from strategies without validating with patient samples should be viewed with caution (1). The strength of our approach is comparative Kaplan-Meier analyses of candidate markers using marrow samples from patients treated on a standardized treatment protocol. Further testing of these markers in a prospective clinical trial is ongoing. Disclosure of Potential Conflicts of Interest No potential conflicts of interest were disclosed. PMID: 19861454 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)

Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions.

Clinical Cancer Research — Tue, 27 Oct 2009 00:00:00 +0100

CONCLUSION: These findings reveal that rituximab-mediated inhibition of intracellular signaling pathways and leading to chemo/immuno-sensitization of resistant B-NHL is Fc independent. (Clin Cancer Res 2009;15(21):6582-94). PMID: 19861448 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)

Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy.

Ann Oncol — Tue, 27 Oct 2009 00:00:00 +0100

CONCLUSION: The use of R-CHOP appears to reduce the overall risk of CNS relapse in patients with DLBCL particularly in patients who achieve a complete response. PMID: 19861575 [PubMed - as supplied by publisher] (Source: Ann Oncol)

Teaching NeuroImages: Primary diffuse large B-cell lymphoma of the cranial vault

Neurology — Mon, 26 Oct 2009 20:01:27 +0100

(Source: Neurology)

One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet’s disease refractory to standard immunosuppressive drugs

Rheumatology International — Mon, 26 Oct 2009 17:59:08 +0100

Abstract The aim of the study was to assess the long-term efficacy and safety of Infliximab therapy in the treatment of patients with Behçet’s disease refractory to standard immunosuppressive agents. Twenty-one patients that did not respond to corticosteroids and to at least one immunosuppressant (cyclosporin, methotrexate, azathioprine, cyclophosphamide) for the presence of ocular and/or CNS involvement were enrolled. Eighteen patients completed the study up to 54 weeks. Stable doses of prednisone (<10 mg/day) were permitted, immunosuppressants were discontinued at least 4 weeks prior baseline visit. The patients received three infusions of 5 mg/kg Infliximab (at weeks 0, 2 and 6) and then infusions of 5 mg/kg Infliximab every 8 weeks. A...

Masking MALT1: the paracaspase's potential for cancer therapy

The Journal of Experimental Medicine — Mon, 26 Oct 2009 16:19:00 +0100

A key feature of aggressive B cell lymphomas is constitutive NF-B activation, which requires signals from the CARD11–BCL-10–MALT1 (CMB) complex. The unique enzymatic activity of MALT1 degrades one of its binding partners, BCL-10, as well as the NF-B inhibitor A20. New data shows that targeting MALT1 protease activity may be a promising therapeutic strategy for treating aggressive B cell lymphomas. (Source: The Journal of Experimental Medicine)

Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells

The Journal of Experimental Medicine — Mon, 26 Oct 2009 16:19:00 +0100

Diffuse large B cell lymphoma (DLBCL) is the most common type of lymphoma in humans. The aggressive activated B cell–like (ABC) subtype of DLBCL is characterized by constitutive NF-B activity and requires signals from CARD11, BCL10, and the paracaspase MALT1 for survival. CARD11, BCL10, and MALT1 are scaffold proteins that normally associate upon antigen receptor ligation. Signal-induced CARD11–BCL10–MALT1 (CBM) complexes couple upstream events to IB kinase (IKK)/NF-B activation. MALT1 also possesses a recently recognized proteolytic activity that cleaves and inactivates the negative NF-B regulator A20 and BCL10 upon antigen receptor ligation. Yet, the relevance of MALT1 proteolytic activity for malignant cell growth is unknown. Here, we demonstrate preassembled CBM compl...

Radiopathological characteristics of cerebellar malignant glioma in adults

Brain Tumor Pathology — Mon, 26 Oct 2009 05:56:34 +0100

Abstract Our aim was to extract the radiopathological features of cerebellar malignant glioma in adults from the four cases we encountered. All four cases (two men and two women, aged 52–80 years; mean age, 67 years) had a floating sensation or vertigo at the onset of their disease. Initially, these patients were given a diagnosis of cerebellar infarction or cavernous angioma, or had faint abnormalities in the cerebellum that were overlooked. These patients were followed up for 2–14 months (mean, 6 months), and the tumor was detected when their clinical symptoms deteriorated. The tumor was located in the hemisphere in one patient and in the vermis in three patients. MRI revealed ring-like enhancement in two patients and nodular enhancement in two patients. All patients...

Puri-Nethol 50mg tablets (6-mercaptopurine) - Revised SPC

NeLM - SPC Changes — Mon, 26 Oct 2009 00:00:00 +0100

Source: eMC (electronic Medicines Compendium) Area: Other Library Updates > SPC Changes Revised SPC includes updates to: section 4.4 - Reports of hepatosplenic T-cell lymphoma in the inflammatory bowel disease (IBD) population have been received when 6-mercaptopurine is used (an unlicensed indication) in combination with anti-TNF agents (see section 4.8 Undesirable Effects). section 4.8 - Neoplasms benign, malignant and unspecified (including cysts and polyps) Very Rare: secondary leukaemia and myelodysplasia; hepatosplenic T-cell lymphoma in patients with IBD (an unlicensed indication) when used in combination with anti-TNF agents. (Source: NeLM - SPC Changes)

Use of 3'-deoxy-3'-[18f]fluorothymidine pet/ct for evaluating response to cytotoxic chemotherapy in dogs with non-hodgkin's lymphoma

Veterinary Radiology & Ultrasound — Mon, 26 Oct 2009 00:00:00 +0100

Imaging and measurement of proliferation with computed tomography (CT) and positron emission tomography (PET) provide a noninvasive method for improved staging and monitoring of response to cancer treatment. We evaluated prospectively the proliferation marker 3'-deoxy-3'[18F] fluorothymidine (FLT) in the context of FLT-PET/CT for detection of early response, confirmation of posttreatment response, and prediction of relapse in dogs with non-Hodgkin's lymphoma. Nine dogs with non-Hodgkin's lymphoma who were scheduled to receive five cycles of an investigational cytotoxic chemotherapy agent were included. All dogs received baseline FLT-PET/CT imaging immediately before chemotherapy. Intent was to repeat imaging with FLT-PET/CT at various time points: group 1 (n=4), 5 days after initiation of ...

Bendamustine: A New Treatment Option for Chronic Lymphocytic Leukemia

Pharmacotherapy: Official Journal of the American College of Clinical Pharmacy — Mon, 26 Oct 2009 00:00:00 +0100

Pharmacotherapy 29(11): 1375-1384 Abstract Chronic lymphocytic leukemia (CLL) is a slow-growing hematologic malignancy and the most common type of leukemia in the western world. The lifetime risk for developing CLL is 1 in 216 men and women. Unfortunately, CLL is considered incurable with the chemotherapeutic agents available today. Bendamustine is a new agent that was recently added to the available regimens for the treatment of CLL. It was also recently approved for the treatment of non-Hodgkin's lymphoma. Its mechanism of action is unknown, but it contains an alkylating group similar to that of other bifunctional alkylating agents such as chlorambucil, and it also contains a benzimidazole central ring thought to exhibit antipurine-like properties. The United States Food and Drug Adminis...

[Imaging in oncology and international rules for evaluation: the nuclear medicine.]

Bulletin du Cancer — Mon, 26 Oct 2009 00:00:00 +0100

Authors: Bourre JC, Vuillez JP The growing success of isotopic explorations in oncology is related to the number of growing radiotracers and progress in the methods for detection and imaging. Today, the nuclear medicine is able to answer important questions raised by biology and therapeutic progress results from this. The new radiopharmaceutical compounds are able to explore in vivo the metabolism, the proliferation, the hypoxia and the expression of some receptors or antigens in tumor cells. This progress in radiopharmaceuticals design can be combined with the new tools for detection, such as the cameras coupled to a tomodensitometer (TEMP-TDM and TEP-TDM), the new gamma cameras with semiconductors, and the peroperative gamma probes. The nuclear medicine can now be used to determine t...

IL-8 production by macrophages is synergistically enhanced when cigarette smoke is combined with TNF-(

Biochemical Pharmacology — Mon, 26 Oct 2009 00:00:00 +0100

In conclusion, CSM exposure of macrophages up-regulates the expression and the production of IL-8 via reactive oxygen species and NF-(B activation. Moreover, CSM dramatically enhances the production of IL-8 in combination with TNF-(. Based upon the strong synergistic action, a combination therapy directed against ROS and TNF-( could be a new approach to stop the progression in lung damage during emphysema. PMID: 19874800 [PubMed - as supplied by publisher] (Source: Biochemical Pharmacology)

FDA approves pralatrexate for treatment of rare lymphoma.

American Journal of Health-System Pharmacy : AJHP — Sun, 25 Oct 2009 23:48:52 +0100

Authors: Thompson CA PMID: 19850775 [PubMed - in process] (Source: American Journal of Health-System Pharmacy : AJHP)

Lower-Dose Dexamethasone Can Be Used To Treat Newly Diagnosed Myeloma

Health News from Medical News Today — Sun, 25 Oct 2009 07:00:00 +0100

High-dose dexamethasone is a mainstay of therapy for multiple myeloma. (Source: Health News from Medical News Today)

Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT.

Ann Oncol — Sun, 25 Oct 2009 00:00:00 +0100

CONCLUSIONS: Our observations expand the spectrum of HCV-associated lymphomas to include a subset of extranodal MZL characterized by a novel primary 'lipoma-like' subcutaneous presentation and indolent clinical course. PMID: 19858084 [PubMed - as supplied by publisher] (Source: Ann Oncol)

Immunophenotypic variations in mantle cell lymphoma.

American Journal of Clinical Pathology — Sat, 24 Oct 2009 14:00:54 +0100

In this study, we evaluated 52 patients with confirmed diagnoses of MCL and identified variant immunophenotypes in 21 patients (19/48 classical and 2/4 variant MCLs), including CD5- in 6 (12%) of 52, CD10+ in 4 (8%) of 50, CD23+ in 10 (21%) of 48, and FMC7- in 4 (11%) of 37 cases. Three cases showed variations in 2 antigens, including CD5-/CD23+, CD10+/FMC7-, and CD23+/FMC7-; they were all classical MCLs. One blastoid variant MCL was CD23+, and one was FMC7-. Evaluation for proliferation index by immunohistochemical analysis for Ki-67 demonstrated no significant difference between MCLs with variant immunophenotypes and MCLs with typical immunophenotypes. The high proliferation index (>60%) was exclusively seen in the blastoid and pleomorphic variants. Our results indicate that immunophe...

T-cell receptor gene rearrangement and CD30 immunoreactivity in traumatic ulcerative granuloma with stromal eosinophilia of the oral cavity.

American Journal of Clinical Pathology — Sat, 24 Oct 2009 14:00:47 +0100

We examined the immunoreactivity for CD30 and T-cell receptor (TCR) gamma gene rearrangement in 37 TUGSE cases. Clonal TCR gene rearrangements were demonstrated in 7 (24%) of 29 cases with amplifiable DNA, and the morphologic features and CD30 immunoreactivity of these cases did not differ from those with polyclonal TCR gene rearrangements. Clinical follow-up was available for 5 of 7 TUGSE cases with clonal TCR gene rearrangement for an average period of 1.75 years after the initial biopsy or excision, and there was no evidence of local recurrence or development of systemic T-cell lymphoproliferative disorder. Without morphologic and/or clinical evidence of lymphoma, T-cell clonality and/or CD30 positivity in these lesions is not indicative of malignancy and should be interpreted with caut...

Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma.

American Journal of Clinical Pathology — Sat, 24 Oct 2009 14:00:44 +0100

Authors: Gupta R, Bhaskar A, Kumar L, Sharma A, Jain P Presence of normal plasma cells (PCs), hemodilution of bone marrow aspirate, and changes in the immunophenotype are important considerations in minimal residual disease (MRD) assessment in multiple myeloma (MM). We evaluated 124 subjects-107 with MM, 11 with Hodgkin lymphoma, and 6 allogeneic stem cell transplantation donors-for the immunophenotype of neoplastic, reactive, and normal PCs respectively. Of the patients with MM, 36 were evaluated for MRD and 23 for a change in immunophenotype after chemotherapy. The immunophenotype of normal and reactive PCs was similar and differed from that of neoplastic PCs with respect to CD19, CD45, CD56, CD52, CD20, and CD117. At least 2 antigens were aberrantly expressed in all cases and 3 in 9...

Significant CD5 expression on normal stage 3 hematogones and mature B Lymphocytes in bone marrow.

American Journal of Clinical Pathology — Sat, 24 Oct 2009 14:00:42 +0100

Authors: Fuda FS, Karandikar NJ, Chen W B-cell maturation from hematogones to mature B cells in bone marrow exhibits a consistent, complex spectrum of sequential antigen expression. CD5 expression, however, has not been characterized. We studied the dynamics of CD5 expression on developing B cells by 4-color flow cytometry in 32 patients, aged 9 months to 63 years, with hematogone hyperplasia (>3.5% of total events). The mean percentage of hematogones was 8.1%. We demonstrate consistent CD5 expression on normal, polytypic B cells in a continuum, predominantly at later stages of maturation, specifically on stage 3 hematogones and mature B cells. Awareness of this normal pattern of CD5 expression on B-cell subsets has implications in the analysis of minimal residual disease of CD5+ B-...

The Reply

The American Journal of Medicine — Sat, 24 Oct 2009 13:21:24 +0100

It has long been appreciated that Cullen's and Grey Turner's signs are both not specific for acute pancreatitis but can occur in a myriad of pathologic processes all involving intra- and retroabdominal hemorrhage. Indeed, reports in the literature also comprise cases of metastatic thyroid cancer, esophageal cancer, intra-abdominal non-Hodgkin's lymphoma, and amoebic liver abscess that are rarely associated with the occurrence of these body wall ecchymoses. This list also encompasses a variety of other clinical conditions. However, many cases with Cullen's or Grey Turner's signs are attributable to acute pancreatitis. Hemorrhage during acute pancreatitis in combination with the release of pancreatic enzymes seems to facilitate the spread of blood via anatomic fasciae becoming visible on the...

Post-Transplant Lymphoproliferative Disorders

Springer Medicine titles — Sat, 24 Oct 2009 03:39:02 +0100

Post-transplant lymphoproliferative disorders are a group of conditions that straddle the borders between infection and malignancy. They were very rare prior to the mid-1980s but now can be expected to develop in 1-10% of transplant recipients. While some cases are reversible with reduction in immunosuppression, more severe forms are indistinguishable from frank lymphomas. This book sets out ... (Source: Springer Medicine titles)

Speckled-like Pattern in the Germinal Center (SLIP-GC), a Nuclear GTPase Expressed in Activation-induced Deaminase-expressing Lymphomas and Germinal Center B Cells [Dna: Replication, Repair, Recombination, and Chromosome Dynamics]

Journal of Biological Chemistry — Fri, 23 Oct 2009 19:16:36 +0100

We identified a novel GTPase, SLIP-GC, with expression limited to a few tissues, in particular germinal center B cells. It lacks homology to any known proteins, indicating that it may belong to a novel family of GTPases. SLIP-GC is expressed in germinal center B cells and in lymphomas derived from germinal center B cells such as large diffuse B cell lymphomas. In cell lines, SLIP-GC is expressed in lymphomas that express activation-induced deaminase (AID) and that likely undergo somatic hypermutation. SLIP-GC is a nuclear protein, and it localizes to replication factories. Reduction of SLIP-GC levels in the Burkitt lymphoma cell line Raji and in non-Hodgkin lymphoma cell lines resulted in an increase in DNA breaks and apoptosis that was AID-dependent, as simultaneous reduction of AID abrog...

Involvement of tyrosine phosphatase CD45 in apoptosis

Apoptosis — Fri, 23 Oct 2009 18:44:17 +0100

Abstract CD45 is a transmembrane molecule with phosphatase activity expressed in all nucleated haematopoietic cells and plays a major role in immune cells. It is a protein tyrosine phosphatase that is essential for antigen-receptor-mediated signal transduction by regulating Src family members that initiate TCR signaling. CD45 is being attributed a new emerging role as an apoptosis regulator. Cross-linking of the extracellular portion of the CD45 by monoclonal antibodies and by galectin-1, can induce apoptosis in T and B cells. Interestingly, this phosphatase has also been involved in nuclear apoptosis induced by mitochondrial perturbing agents. Furthermore, it is involved in apoptosis induced by HIV-1. CD45 defect is implicated in various diseases such as severe-combined i...

De novo transcriptome assembly with ABySS

Bioinformatics — Fri, 23 Oct 2009 13:34:21 +0100

Motivation: Whole transcriptome shotgun sequencing data from non-normalized samples offer unique opportunities to study the metabolic states of organisms. One can deduce gene expression levels using sequence coverage as a surrogate, identify coding changes or discover novel isoforms or transcripts. Especially for discovery of novel events, de novo assembly of transcriptomes is desirable. Results: Transcriptome from tumor tissue of a patient with follicular lymphoma was sequenced with 36 base pair (bp) single- and paired-end reads on the Illumina Genome Analyzer II platform. We assembled ~194 million reads using ABySS into 66 921 contigs 100 bp or longer, with a maximum contig length of 10 951 bp, representing over 30 million base pairs of unique transcriptome sequence, or roughly 1% of the...

Subcutaneous panniculitis-like T-cell lymphoma

Anais Brasileiros de Dermatologia — Fri, 23 Oct 2009 12:59:34 +0100

Linfoma subcutâneo de células T paniculite-símile foi recentemente reconhecido como entidade clínico-patológica. Paciente do sexo feminino, 17 anos, relatou nodosidades eritêmato-violáceas e depressões nos membros e abdome há três anos e discreta perda ponderal, sem outros sintomas gerais. Adenomegalia, visceromegalias e infiltração da medula óssea estavam ausentes, e a histopatologia da pele mostrou densa infiltração de linfócitos atípicos CD3/CD8 no subcutâneo. A quimioterapia interrompeu o surgimento de novas lesões com remissão das pré-existentes no seguimento de oito meses. Aspectos imunofenotípicos e moleculares são relevantes para elucidação diagnóstica e avaliação do prognóstico.Subcutaneous panniculitis-like T-cell lymphoma is extremely rare and has re...

Genetics: Becoming mobile

Nature Reviews Cancer — Fri, 23 Oct 2009 12:43:27 +0100

Nature Reviews Cancer 9, 766 (2009). doi:10.1038/nrc2750 Author: Meera Swami Mouse models have provided valuable insights into cancer biology, but have been limited in terms of performing unbiased genetic screens. Now an in vivo RNA interference screening approach has been used to identify determinants of lymphoma progression, showing that genes involved in cell motility (Source: Nature Reviews Cancer)

Pixantrone Produces High Rates Of Complete Remission In Multiple Relapsed And Refractory Indolent And Aggressive Non-Hodgkin's Lymphoma

Health News from Medical News Today — Fri, 23 Oct 2009 09:00:00 +0100

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that Dr. (Source: Health News from Medical News Today)

Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase-type plasminogen activator.

J Cell Mol Med — Fri, 23 Oct 2009 00:00:00 +0100

Authors: Schrötzlmair F, Kopitz C, Halbgewachs B, Lu F, Algül H, Brünner N, Gänsbacher B, Krüger A ABSTRACT Paradoxically, not only proteinases but also their inhibitors can correlate with bad prognosis of cancer patients, underlining the evolving concept of the protease web as the complex interplay between proteinases, their inhibitors, and effector molecules. Elevated levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) render the liver more susceptible to metastasis by triggering urokinase plasminogen activator (uPA) expression as well as hepatocyte growth factor (HGF) signalling, thereby leading to the fatal scattered infiltration of metastasizing tumour cells throughout the parenchyma of the target organ. Here, we investigated whether host uPA is a ...

Insight into the molecular pathogenesis of hairy cell leukaemia, hairy cell leukaemia variant and splenic marginal zone lymphoma, provided by the analysis of their IGH rearrangements and somatic hypermutation patterns

British Journal of Haematology — Thu, 22 Oct 2009 23:00:00 +0100

(Source: British Journal of Haematology)

Serum interleukin-27 levels in patients with cutaneous T-cell lymphoma

Clinical And Experimental Dermatology — Thu, 22 Oct 2009 23:00:00 +0100

(Source: Clinical And Experimental Dermatology)

Adipocytokines in relation to Hodgkin lymphoma in children

Pediatric Blood and Cancer — Thu, 22 Oct 2009 23:00:00 +0100

Retrospective analysis of non-anaplastic peripheral T-cell lymphoma in pediatric patients in Japan

Pediatric Blood and Cancer — Thu, 22 Oct 2009 23:00:00 +0100

Reports of non-anaplastic peripheral T-cell lymphoma (PTCL) in pediatric patients are relatively rare.We performed a retrospective analysis in patients with PTCL over an 18-year period (1991-2008).We could analyze clinical data in 21 patients with non-anaplastic PTCL; 10 were female and 10 male. Median age of onset was 11 years (range: 1-21 years). There were nine patients with PTCL, not otherwise specified (PTCL-NOS); ten with extranodal NK/T-cell lymphoma, nasal type; one with angioimmunoblastic T-cell lymphoma; and one with subcutaneous panniculitis-like T-cell lymphoma. Initial lesions involved cervical lymph nodes in five patients, and the skin in five patients. In five patients, hemophagocytic syndrome (HPS) was the initial clinical feature. There were 12 patients with advanced stage...